Advanced Cell Technology announces IND timetables for therapeutic programs

By Elaine Rigoli

Tampa, Fla., May 15 - Advanced Cell Technology, Inc. announced timetables for filing Investigational New Drug applications for each of its key therapeutic programs, which include its Retinal Pigment Epithelium, Hemangioblast and Dermal programs.

Based on the company's preclinical studies to date, the company said it expects to file its initial IND application for its RPE Program for the treatment of macular degeneration in the second half of 2007.

Additionally, the company plans to file IND applications in 2008 for both its Hemangioblast and Dermal programs.

The company is conducting preclinical studies for its Hemangioblast Program for the treatment of various cardiovascular diseases including heart disease, coronary artery disease and stroke, as well as ischemia of the eye and limbs.

Advanced Cell Technology is a biotechnology company based in Alameda, Calif., and Worcester, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.